TREMFYA(r) (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
October 13, 2026
October 13, 2026
NEW BRUNSWICK, New Jersey, Oct. 13 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:
* * *
TREMFYA(r) (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
*
Spring House, Pa. (October 12, 2026) - Johnson & Johnson today announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable efficacy . . .
* * *
TREMFYA(r) (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
*
Spring House, Pa. (October 12, 2026) - Johnson & Johnson today announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable efficacy . . .